Morgan Stanley Maintains Biohaven at Overweight, Raises Price Target to $21
Morgan Stanley has reaffirmed its 'Overweight' rating on Biohaven (BHVN) and increased its price target for the company's shares from $19 to $21.
Stocks · News reference
Biohaven Announces Progress Across Its Graves' Disease Program
Biohaven is advancing its Graves' disease treatment candidate, BHV-1300, with ongoing Phase 3 clinical trials and the presentation of new scientific data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy Rating
Deutsche Bank has revised its 12-month price target for Biohaven Ltd. to $23 from the previous $26, while maintaining a Buy rating on the stock.
Biohaven Ltd. Analyst Price Target Adjusted to $25
Analysts have updated the 12-month price target for Biohaven Ltd. to $25, reflecting a slight decrease from the previous average of $25.17.
Biohaven Reports Q3 2026 Financial Results and Regulatory Updates
Biohaven announced its third-quarter 2026 financial results, including an adjusted loss of $0.73 per share, and provided updates on its clinical pipeline and regulatory progress.
Biohaven Presents Data on BHV-1420 at ASN Kidney Week 2026
Biohaven Ltd. showcased its investigational TRAP extracellular protein degrader, BHV-1420, in an oral presentation at the ASN Kidney Week 2026 conference.